Blogger's Note: several articles posted on the same subject, some easier to read (plain english)
Largest Trial of VTE Prophylaxis in Cancer Patients on Chemo:
The new trial adds to previous data showing a benefit, but it is up to individual patients to decide whether or not to use this option, says editorialist.
Medscape Medical News
February 15, 2012 — The largest study to date of thromboprophylaxis
in cancer patients on chemotherapy shows that the use of a heparin
product significantly reduces the risk for thromboembolic events with no
apparent increase in bleeding.
The positive results add to several previous studies showing a
benefit from thromboprophylaxis in cancer patients, and reopen an
ongoing debate about whether such use should be routine.
The latest study, known as SAVE-ONCO, was conducted in 3212 cancer
patients who were beginning chemotherapy and used the hemisynthetic
ultra-low-molecular-weight heparin (LMWH) semuloparin (Visamerin,
Sanofi; marketed in Europe, but not available in the United States).
The study, by Giancarlo Agnelli, MD, from the University of Perugia,
Italy, and colleagues, is published in the February 16 issue of the New England Journal of Medicine......
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.